Directory / Industry
Biotech
2 founders building in Biotech.
Kazuma Kishida
Named Forbes 30 Under 30 Asia; raised Series A (¥1B) plus prior funding totaling ~¥1.42B for a novel stem-cell fertility platform covered by TechCrunch and Forbes.
Akifumi Morinaka
Rege Nephro closed a ~$10.6M/¥1.22B round for its ADPKD drug candidate RN-014, but Morinaka is CEO rather than the company's founder (founder is Prof. Kenji Osafune).
